SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON) (NCT05254197) | Clinical Trial Compass
RecruitingNot Applicable
SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)
South Korea3,000 participantsStarted 2001-01-01
Plain-language summary
The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 2001, and who have had magnetic resonance (MR) re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not be needed at the first visit to the hospital. In all MRs taken by patients, the date of imaging and the volume of the tumor are measured, and we aim to establish a natural growth history for non-malignant brain tumors.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria for retrospective cohort
* Patients with radiologically diagnosed brain neoplasm of CNS WHO grade 2 or less since 1998
* Asymptomatic at first visit to the hospital
* Patients who, based on the up-to-date knowledge, did not necessarily require immediate treatment at the first hospital visit
* Patients who have had two or more MRs at least 3 months apart
* No previous radiotherapy or radiosurgery for the brain lesion
* 18 years old or more
Inclusion Criteria for prospective cohort
* Patients with newly diagnosed brain neoplasm of CNS WHO grade 2 or less
* Asymptomatic at first visit to the hospital
* Patients who, based on the up-to-date knowledge, did not necessarily require immediate treatment at the first hospital visit and who are going to take follow-up MR exams
* No previous radiotherapy or radiosurgery for the brain lesion
* 18 years old or more
* Patients who agree to participate by written consent
Exclusion Criteria
* Patients who lost follow-up before the second MR exam
* Patients requiring immediate treatment due to worsening of symptoms within 3 months of the first MR exam
* Patients suspected to have other than a neoplasm at follow-up MR exams
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.